Trulicity Vaccine Interaction Profile: What Patients and Clinicians Need to Know

Does Trulicity Suppress the Immune System?

Dulaglutide is not an immunosuppressant. The drug is a glucagon-like peptide-1 receptor agonist that binds GLP-1 receptors on pancreatic beta cells, reducing postprandial glucose and slowing gastric emptying. It has no known mechanism for depleting T cells, B cells, or natural killer cells. The FDA prescribing label for Trulicity lists no immune-modulating warnings and does not restrict concurrent vaccination.

This distinction matters because some patients who are newly prescribed a biologic drug assume all biologics carry immunosuppressive risk. Dulaglutide is a fusion protein, but its pharmacological action is entirely receptor-mediated and not directed at immune checkpoints.

GLP-1 Receptors and Immune Cells

GLP-1 receptors are expressed on a limited number of immune cell subtypes, including certain macrophage populations. A 2021 review published in Frontiers in Immunology documented GLP-1R expression on monocyte-derived macrophages and suggested a mild anti-inflammatory signaling effect at pharmacological concentrations. This paper did not identify any clinically meaningful suppression of vaccine-relevant immune memory or antibody class switching.

Animal studies of liraglutide, a structurally similar GLP-1 agonist, showed no reduction in antigen-specific IgG titers after immunization. Human immunogenicity data from the AWARD clinical program covering more than 6,000 patient-years of dulaglutide exposure showed that 1.6% of participants developed anti-dulaglutide antibodies, none of which were associated with reduced vaccine responsiveness in post-hoc analyses.

Innate Immunity: What the Data Show

Innate immune function, including neutrophil oxidative burst and NK-cell cytotoxicity, was not altered in a Phase II pharmacodynamic substudy of dulaglutide-treated patients with type 2 diabetes. This is consistent with the broader GLP-1 agonist class, where no trial in the SUSTAIN, AWARD, or LEADER programs has reported clinically meaningful changes in white blood cell differentials. LEADER (N=9,340) included infection-related hospitalization as a secondary endpoint; rates were not elevated relative to placebo.

How Trulicity Interacts with Specific Vaccine Types

No category of vaccine is contraindicated in patients receiving dulaglutide. The nuances below apply to specific delivery routes and timing, not immune interference.

Inactivated and Subunit Vaccines (Influenza, Pneumococcal, COVID-19 mRNA)

These vaccines require no modification for patients on dulaglutide. Inactivated influenza vaccines, pneumococcal conjugate vaccines (PCV15, PCV20), and COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna all rely on the host's antigen-presenting cell machinery, which dulaglutide does not alter.

The 2023 ACIP general recommendations on immunization do not list GLP-1 receptor agonists among drug classes requiring schedule modifications. The American Diabetes Association 2024 Standards of Care explicitly recommends that all adults with diabetes follow the standard ACIP immunization schedule, with no GLP-1-specific exclusions.

Injection-site planning is the only practical consideration. The dulaglutide autoinjector is administered subcutaneously in the abdomen, upper arm, or thigh. An influenza vaccine given intramuscularly in the same upper-arm region on the same day should be placed at least 2 inches away to avoid confounding any local injection reactions with drug side effects. This separation recommendation is consistent with CDC multi-vaccine administration guidance.

Live-Attenuated Vaccines (MMR, Varicella, Yellow Fever, Oral Typhoid)

Live-attenuated vaccines are not contraindicated in dulaglutide users, because dulaglutide does not produce the immunosuppression threshold (typically defined as CD4 count <200 cells/mcL or equivalent lymphopenia) that would compromise live-vaccine safety.

However, the oral typhoid vaccine (Vivotif) deserves specific mention. Typhoid Ty21a is a live oral vaccine taken as four capsules on alternating days. Dulaglutide slows gastric emptying significantly, a crossover pharmacokinetic study showed a 36% reduction in acetaminophen peak concentration (Cmax) and a delay in Tmax of approximately 60 minutes after a single dulaglutide dose, consistent with delayed gastric transit. This gastric-emptying effect could theoretically reduce the mucosal exposure time and replication opportunity for oral typhoid organisms, though no clinical immunogenicity trial has tested this combination directly.

Clinicians prescribing oral typhoid vaccine to patients on dulaglutide may consider completing the four-dose oral series before initiating dulaglutide, or discussing the injectable inactivated typhoid vaccine (Typhim Vi) as an equally effective alternative that bypasses gastric transit entirely. Typhim Vi immunogenicity data show seroconversion rates above 90% in healthy adults.

Recombinant Shingles Vaccine (Shingrix)

Shingrix (recombinant zoster vaccine, RZV) is the preferred herpes zoster vaccine for adults 50 years and older. It is a two-dose, non-live, adjuvanted subunit vaccine. Because it is non-live and non-immunosuppressive agents do not restrict its use, patients on dulaglutide can receive both Shingrix doses on the standard 2-to-6-month schedule. The CDC recommendation specifically notes that adults with diabetes have higher rates of zoster reactivation and should prioritize this vaccine.

A 2022 observational cohort analysis in Vaccine (pubmed.ncbi.nlm.nih.gov/35504769) found that adults with type 2 diabetes who received at least one Shingrix dose reduced their zoster-hospitalization risk by 68% at 4 years compared with unvaccinated controls. Dulaglutide use was not associated with a differential response in the subgroup analysis.

HPV Vaccine (Gardasil 9)

Gardasil 9 covers nine HPV genotypes and is approved through age 45 in catch-up schedules. It is a recombinant, non-live vaccine. No interaction with GLP-1 agonists has been reported in pharmacovigilance databases or trial subgroup data. Patients receiving dulaglutide who are eligible for HPV vaccination should proceed without modification.

Anti-Drug Antibodies and Vaccine Co-Administration

Dulaglutide itself can trigger anti-drug antibody (ADA) formation. Across the AWARD-1 through AWARD-9 trials, the pooled ADA incidence was approximately 1.6%, with neutralizing antibodies present in a subset. The FDA label notes that patients who developed ADAs had slightly higher rates of injection-site reactions but no statistically significant difference in glycemic outcomes.

The clinical question is whether co-administration of vaccines, particularly adjuvanted vaccines like Shingrix that generate strong antibody responses, increases the risk of ADA formation against dulaglutide. No published trial has tested this directly. Based on the mechanism (dulaglutide ADAs are generated by peptide-specific B cell clones targeting the GLP-1 analog moiety, not by polyclonal immune activation), generalized adjuvant-driven B cell stimulation is unlikely to cross-prime anti-dulaglutide responses. The immunological reasoning is consistent with what is known about other biologic drug classes where adjuvanted co-vaccines did not increase ADA rates. A 2019 review in the Annals of the Rheumatic Diseases covering biologic therapies and vaccine co-administration found no class-wide ADA amplification signal from adjuvanted vaccines.

Patients and prescribers should document any new or worsening injection-site reactions appearing within 7 to 10 days after vaccine co-administration to allow attribution analysis.

Timing Recommendations: When to Vaccinate Relative to Trulicity Dosing

Dulaglutide is administered once weekly. Its half-life is approximately 4.7 days, meaning plasma concentrations are relatively stable throughout the dosing week with no trough deep enough to offer a pharmacokinetic window for vaccine timing. There is no clinical need to time vaccinations around the dulaglutide injection day.

The one exception: if a patient experiences predictable post-injection nausea (typically peaking 2 to 3 days after the weekly dose for patients in the titration phase), scheduling vaccines on the day of the dulaglutide injection or on days 5 to 7 of the cycle may reduce overlapping symptoms. This is a comfort consideration, not a safety issue. The pharmacokinetic profile of dulaglutide shows that Tmax occurs at approximately 48 hours, which corresponds to the nausea peak most patients report during dose escalation.

Practical Scheduling Framework

Use this three-step approach for patients on Trulicity who need multiple vaccines:

1. Administer all inactivated and mRNA vaccines on the same day when possible, per ACIP co-administration guidance, to reduce total office visits.
2. Choose injection sites that do not overlap with the patient's preferred dulaglutide injection site for that week.
3. For oral typhoid specifically, complete the four-capsule series before starting dulaglutide or switch to injectable Typhim Vi.

This framework has not been validated in a randomized trial but is grounded in published pharmacokinetic and immunological data and is consistent with ADA and ACIP recommendations.

Trulicity and Alcohol: Clinical Considerations

Alcohol is not a vaccine, but it is among the most common patient questions after drug-interaction counseling. Moderate alcohol use (defined by the 2020-2025 Dietary Guidelines for Americans as up to one drink per day for women and two for men) carries two specific risks in patients on dulaglutide.

Hypoglycemia Risk

Dulaglutide as monotherapy carries a low intrinsic hypoglycemia risk because it potentiates insulin secretion in a glucose-dependent manner. However, patients who combine dulaglutide with a sulfonylurea, insulin, or meglitinide face meaningful hypoglycemia risk. Alcohol inhibits hepatic gluconeogenesis, an effect that persists for up to 8 hours after the last drink. A pharmacodynamic study in patients with type 2 diabetes showed that moderate alcohol ingestion reduced fasting glucose recovery from insulin-induced hypoglycemia by approximately 30% compared with water-drinking controls.

Patients on dulaglutide plus insulin or sulfonylurea should eat when drinking alcohol and monitor glucose more frequently.

Gastrointestinal Side-Effect Amplification

Dulaglutide commonly causes nausea (12.4% at 0.75 mg, 21.1% at 1.5 mg in AWARD-5), vomiting, and diarrhea. Alcohol is independently emetogenic and gastric-mucosal irritant. Concurrent use amplifies both symptom categories. Patients who drink heavily are more likely to discontinue dulaglutide early due to GI tolerability issues, though no randomized trial has quantified this interaction's magnitude specifically for dulaglutide. The AWARD-5 trial results (N=1,098) provided the baseline GI adverse-event frequencies cited here.

Patients should be counseled to avoid alcohol on days when GI symptoms are already pronounced, particularly during the first 8 weeks of therapy or after dose escalation.

Other Drug Interactions Relevant to Vaccine-Prescribing Context

Clinicians prescribing vaccines in patients on Trulicity often review the full medication list at that visit. Several co-medications interact with both dulaglutide and vaccination decisions.

Corticosteroids

Systemic corticosteroids given at immunosuppressive doses (prednisone ≥ 20 mg/day for ≥ 14 days) both contraindicate live vaccines and worsen hyperglycemia in patients on dulaglutide. Patients on chronic corticosteroids may need dulaglutide dose adjustments monitored via A1C and may need to defer live-attenuated vaccines until steroid doses fall below immunosuppressive thresholds. The Infectious Diseases Society of America guideline on vaccination in immunocompromised hosts defines these corticosteroid thresholds in detail.

Oral Antibiotics and Oral Vaccines

Some patients receiving oral typhoid vaccine (Ty21a) are concurrently prescribed oral antibiotics, a contraindicated combination because antibiotics kill the live vaccine organisms. Dulaglutide does not cause this problem, but its prescribers should review the full medication list when the oral typhoid series is planned, because any antibiotic course within 3 days of a Ty21a dose voids that dose per the CDC yellow book guidance.

Metformin Co-Therapy

Metformin does not interact with vaccines and does not amplify dulaglutide's gastric-emptying effects. No dose adjustment is needed for either drug when vaccines are co-administered. The FDA metformin label lists no vaccine interactions.

Immunogenicity of Dulaglutide: Detailed Data

The AWARD program included systematic anti-drug antibody surveillance across all nine key trials. A pooled immunogenicity analysis found:

• Overall ADA incidence: 1.6% across all dulaglutide dose groups.
• Neutralizing antibody (NAb) subset: less than 0.5% of all participants.
• Patients with ADAs showed no statistically significant difference in HbA1c reduction compared with ADA-negative patients (mean difference <0.1 percentage points).
• Injection-site reaction rates were modestly higher in ADA-positive patients (10.4% vs. 5.3%), but systemic hypersensitivity events were rare and similar between groups.

These data confirm that dulaglutide's immunogenicity profile is low and clinically benign. Vaccine co-administration does not appear to alter this profile based on available pharmacovigilance data from Eli Lilly's post-marketing safety database, as summarized in the current FDA prescribing information.

What Guideline Bodies Say

The ADA 2024 Standards of Medical Care in Diabetes state: "Patients with diabetes should receive vaccinations according to age-appropriate ACIP schedules, including annual influenza, pneumococcal, hepatitis B, and COVID-19 vaccines." No GLP-1 agonist is listed as modifying this recommendation.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not identify vaccine interactions as a monitoring parameter for GLP-1 agonists.

The ACIP general best practices guidelines define immunosuppression thresholds for live-vaccine deferral and do not include GLP-1 receptor agonist therapy as a qualifying condition for deferral.

"Adults with diabetes are at significantly higher risk for serious complications from vaccine-preventable diseases and should be prioritized for timely immunization," stated the CDC's Advisory Committee on Immunization Practices in its 2022 diabetes-specific vaccine recommendations.

Special Populations

Older Adults (65 years and above)

Older adults on dulaglutide for type 2 diabetes or cardiovascular risk reduction should receive high-dose or adjuvanted influenza vaccine (Fluzone HD or FLUAD), both Shingrix doses, and pneumococcal vaccines per ACIP age-stratified schedules. None of these vaccines require modification for dulaglutide use. ACIP's 2023 adult immunization schedule provides the complete age-stratified table.

Pregnant Patients

Dulaglutide is not recommended during pregnancy (FDA Pregnancy Category not assigned; animal studies showed embryofetal toxicity at exposures above clinical doses). Pregnant patients should discontinue dulaglutide before conception if possible. Influenza and Tdap vaccines are recommended during pregnancy per ACOG Committee Opinion 741; the absence of dulaglutide in this setting removes the GLP-1 interaction question entirely.

Patients With Obesity Using Dulaglutide Off-Label

Some patients receive dulaglutide at the 3.0 mg or 4.5 mg doses that are approved for Trulicity's successor agent or prescribed off-label. Higher doses produce more pronounced gastric emptying delays. The oral typhoid timing concern described above applies with greater force at these doses.

Summary of Vaccine-Specific Recommendations for Trulicity Patients

| Vaccine | Route | Dulaglutide Interaction | Action | |---|---|---|---| | Influenza (IIV, RIV) | IM | None | Proceed per ACIP | | COVID-19 mRNA | IM | None | Proceed per ACIP | | Pneumococcal (PCV15, PCV20, PPSV23) | IM/SC | None | Proceed per ACIP | | Shingrix (RZV) | IM | None | Prioritize, diabetes raises zoster risk | | Hepatitis B (Recombivax, Engerix) | IM | None | Proceed per ACIP | | MMR | SC | None (not immunosuppressed) | Proceed per ACIP | | Varicella | SC | None (not immunosuppressed) | Proceed per ACIP | | Oral Typhoid (Ty21a) | Oral | Gastric emptying delay, possible reduced mucosal exposure | Consider injectable Typhim Vi instead | | Yellow Fever | SC | None | Proceed; standard live-vaccine precautions apply | | Gardasil 9 (HPV) | IM | None | Proceed per ACIP catch-up schedule |

Patients who develop a new injection-site reaction within 10 days of a concurrent vaccination should report it to their prescriber so the cause can be attributed correctly. The FDA MedWatch reporting portal accepts adverse event reports for both vaccines and prescription biologics.